Loss of Arginase 2 Promotes Lung Metastasis in immune-competent hosts via Nitric Oxide Synthase 2-Dependent Th17 Response
Distant metastasis is the leading cause of mortality in many cancers. Although metabolic reprogramming is recognized as a hallmark of cancer, how tumor-intrinsic metabolic enzymes regulate tumor-immune crosstalk during metastatic progression remains poorly understood. Here, using a high-throughput functional CRISPR-Cas9 screen targeting metabolic genes in an orthotopic 4T1 murine mammary carcinoma model of spontaneous lung metastasis, we identify a selective enrichment of arginase 2 (ARG2)-deficient tumor cells in metastatic lungs of immunocompetent but not RAG1-deficient mice, indicating a lymphocyte-dependent mechanism. Loss of ARG2 enhances spontaneous lung metastasis without affecting primary tumor growth. Further, metastatic outgrowth in the lung is not affected when tumor cells are injected intravenously, indicating that ARG2 regulates an early stage of the metastatic cascade. Mechanistically, ARG2 deficiency upregulates nitric oxide synthase 2 (NOS2), resulting in increased nitric oxide production, accumulation of cytosolic DNA, and activation of the cGAS-STING-NF-{kappa}B pathway, leading to upregulation of inflammatory cytokines. ARG2-deficient tumors exhibit an immunosuppressive tumor microenvironment characterized by enrichment of Th17 cells and reduced anti-tumor immune populations. Functionally, Th17 cells enhance tumor cell migration in vitro and promote spontaneous lung metastasis in vivo. Genetic deletion of NOS2 attenuates cytosolic DNA accumulation, reduces STING-NF-{kappa}B activation, restores anti-tumor immunity, and suppresses ARG2 deficiency-driven metastatic burden in vivo. Collectively, these findings define a tumor cell-intrinsic ARG2-NOS2 axis that regulates inflammatory signaling and the tumor microenvironment to promote metastasis, highlighting a targetable vulnerability in metastatic breast cancer.